Pharmaceutical Sales and Marketing Articles

The European Union is currently revising its rules governing animal testing, but industry is not entirely happy with the proposed new Directive. The current Directive, which has been in force since 1986, was designed to harmonize the rules for animal testing across the whole EU. However, some member states have implemented more stringent standards, while others stick to the bare minimum.

This year's pipeline might be best remembered for drugs that evaporated at the last moment. Sanofi-Aventis gave up on Acomplia, one of the most celebrated drug candidates in the Pipeline Report for three years running, and took a whole crop of CB1 obesity drugs down with it. Flurizan, last year's headliner in Alzheimer's therapy, proved less than efficacious.

Doing deals has become Big Pharma's lifeline, and that fact is more evident in 2008 than ever before. With patents on megablockbusters falling like dominoes, and in-house R&D no match for vanishing sales, industry giants are reaching into their deep pockets to bridge the growth gap. This has drugmakers rolling the dice on more products that are in early-stage development.

Google the name of any well-known drug, and in addition to a brand Web page, a Wikipedia entry, and listings in a handful of directories, you'll see dozens, if not hundreds, of online pharmacies offering to send you the product in discreet packaging at rock-bottom prices. This raises a scary question: If you send in your money, what will you get?

In Europe, state controlled healthcare decisions create as many problems as they do answers
Nov 1, 2008
By: Sarah Houlton
Pharmaceutical Executive

Sarah Houlton

The Presidential and Vice Presidential candidates show that length of resume isn't the clearest proof of ability to lead
Nov 1, 2008
By: Sander Flaum, Flaum Partners
Pharmaceutical Executive

Sander A. Flaum

Somehow, the public has got it into its head that FDA should inspect all the world's drug plants. Aren't there better ways to ensure the safety of imported drugs?
Nov 1, 2008
By: Patrick Clinton
Pharmaceutical Executive

Patrick Clinton

The failure of a clinician to disclose nearly $1 million in industry payments has turned the spotlight on conflicts of interest in the biomedical research world. Sen. Charles Grassley (R-IA), ranking Republican on the Senate Finance Committee, recently uncovered evidence that psychiatrist Charles Nemeroff of Emory University in Atlanta ignored demands to disclose payments from GlaxoSmithKline.

The pharma industry is filled with awards that take note of the best and brightest companies have to offer. But there's one pharma award that marketing agencies seem to especially appreciate—and that's because doctors dictate the vote.

As patient compliance rates continue to decline, pharmaceutical companies must look beyond their internal adherence programs and consider some of the nifty new gadgets technology vendors are providing the healthcare industry. Sure, some of these contraptions aren't targeted primarily at pharma, but most of them can be adapted to suit various needs.